ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease



    KIRKLAND, Wash., Aug. 7 /CNW/ -- ProteoTech Inc. (ProteoTech) today
announced that it has completed regulatory Investigational New Drug (IND)
requirements and has been cleared by the FDA to initiate its Phase 1 human
clinical trial on Exebryl-1(R), a novel small molecule drug targeting toxic
beta-amyloid protein accumulation for the treatment of Alzheimer's disease.
ProteoTech initiated its Phase 1 human trial on July 29, 2008.
    At the 2008 International Conference on Alzheimer's disease in Chicago
last week, ProteoTech presented remarkable efficacy data in Alzheimer's
transgenic mice, whereby Exebryl-1(R) lowered brain beta-amyloid protein load
by greater than 30-50%, correlating with marked improvements in memory in
these animals. Toxic and insoluble beta-amyloid protein accumulation is
believed to be an important part of the disease progression and memory
impairment observed in all patients with Alzheimer's disease. Data was also
presented demonstrating oral bioavailability and blood-brain-barrier
penetration of Exebryl-1(R).
    Exebryl-1(R) is a novel small molecule drug developed at ProteoTech from
its unique library of small molecule compounds designed to target specific
amyloid diseases. Over six years of pre-clinical in vitro and in vivo testing
led to the development of Exebryl-1(R) that is believed to prevent
beta-amyloid protein formation, deposition, and accumulation at all stages of
the disease progression. In addition, Exebryl-1(R) also contributes to a
reduction and clearance of beta-amyloid protein deposits already existing in
the brain as shown by a significant and marked reduction in brain amyloid
plaques in older Alzheimer's transgenic animals.
    Initial studies suggest that Exebryl-1(R) may also have an important dual
capacity by inhibiting and reducing tau protein from forming paired helical
filaments, important in neurofibrillary tangle formation. The presence of
neurofibrillary tangles in brain containing tau protein is an important
pathological hallmark of Alzheimer's disease. Further studies are ongoing to
confirm these exciting findings. Thus, Exebryl-1(R) may be the first orally
bioavailable small molecule drug that affects both amyloid plaque and
neurofibrillary tangle accumulation, the two major characteristic and
pathological lesions of Alzheimer's disease.
    About ProteoTech: ProteoTech is a private drug development Company
founded in 1996 that is a world-leader in therapeutics and diagnostics
targeting amyloid diseases. With over 165 patents in its intellectual property
estate, ProteoTech is in human clinical trials for its orally active small
molecule drug Exebryl-1(R) for the treatment of mild-to-moderate Alzheimer's
disease. The Company is in late stage pre-clinical development with
Synuclere(TM) for the treatment of Parkinson's disease, and Systebryl(TM) for
the treatment of Systemic Amyloidosis. ProteoTech is also in late stage
pre-clinical development for a novel small peptide called PeptiClere(TM) as a
nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is
developing a novel small molecule compound for the treatment of amyloidosis
associated with type 2 diabetes. For further information, go to
http://www.proteotech.com or contact Steve Runnels, CEO at
runnels@proteotech.com.




For further information:

For further information: Steve Runnels, CEO of ProteoTech Inc.,
+1-425-820-2703, runnels@proteotech.com Web Site: http://www.proteotech.com

Organization Profile

PROTEOTECH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890